Charles Lynde, MD, is an associate professor in the Department of Medicine at the University of Toronto. He is the also Chief Medical Director of Lynde Institute for Dermatology and Lynderm Research.

, defined by a Severity of Alopecia Tool (SALT) score of 50 or greater, has left clinicians with few systemic options for adults and adolescents with extensive or total scalp hair loss. Charles Lynde, MD, FRCPC, medical director of the Lynde Institute for Dermatology & Lynderm Research in Markham, Ontario, Canada, co-authored new phase 3 data addressing this gap.

UP-AA1 and UP-AA2, 2 replicate phase 3 randomized trials published in 

 Dermatology, assigned 1399 adults and adolescents with severe disease to once-daily upadacitinib 15 mg, 30 mg, or placebo for 24 weeks.¹ Participants averaged more than a decade of disease duration, and roughly half entered with SALT scores of 95 or higher, indicating near-total scalp hair loss.¹ The trials included 118 adolescents aged 12 - 17 years, broadening the evidence base beyond currently available adolescent options.²

At Week 24, 45.2% and 55.0% of UP-AA1 patients on the 15-mg and 30-mg doses, respectively, reached the primary endpoint of SALT score ≤20 versus 1.5% on placebo (

<.001).¹ UP-AA2 showed comparable results, with 44.6% and 54.3% reaching the endpoint versus 3.4% on placebo, and separation from placebo emerged by Week 8 in both trials.¹ Complete regrowth, defined as SALT 0, occurred in up to 22.5% of treated patients.¹

Achieving SALT score ≤20 corresponds to roughly 80% scalp coverage, a threshold clinicians associate with reduced reliance on wigs and greater tolerance of residual patches. Gains extended beyond the scalp as well, with improvements in eyebrow and eyelash regrowth alongside quality-of-life measures.¹ Below, Lynde discusses the trial population, the clinical significance of the primary endpoint, and why regrowth beyond the scalp matters for patients.

: What made this severe alopecia areata population difficult to treat, and how did the UP-AA trial design address that?

Alopecia areata can present as small localized areas of hair loss, but in this trial we were looking at people with very severe disease. To get into the trial, you had to have a SALT score, a measure of the amount of hair loss, greater than 50, which translates to 50% loss of all your hair. If you and I look at each other, we're both lucky to have all our hair, but people with 50% loss can't hide it, and many patients in the trial had a SALT score of 100, meaning they had completely lost all their hair.

These are severe, or very severe, patients with alopecia areata. Luckily, there have been a number of newer drugs, mostly JAK inhibitors, found to be useful for this condition, taking people who had lost all their hair for seven or eight years and getting it back again. It's quite amazing.

: Clinically, what does hitting 80% scalp coverage by Week 24 mean for a patient in your chair?

 For people getting a complete response, that's a different bar. Complete response means going from SALT 100 to SALT 0 or SALT 10. Some people got down to SALT 20, meaning they still had 20% loss in their scalp, but at that level, you can usually comb over and find ways to make sure other people don't notice it, so you don't have to wear a wig. When you have SALT 100, everybody notices, and you usually have to wear a wig if you want to hide it.

: Why does it matter that eyebrow and eyelash regrowth and quality-of-life scores improved alongside scalp coverage?

 People want to feel normal again once treatment is over. If you got all your hair back on your scalp but you're missing your eyebrows, you look a little funny. Missing your eyebrows and eyelashes might seem like nothing, but they protect your eyes. Without them, dirt, pollen, and bacteria in the air get into your eyes, so you're getting conjunctivitis all the time. People also miss nose hair in this condition, which acts as a filter to protect your lungs from upper respiratory tract infections, so you want regrowth on the scalp and the face at the same time.

Interestingly, some patients I've had with this and other drugs like it get their eyelashes and eyebrows back, and if they're a guy who doesn't get all their scalp hair back, they're extremely happy because they can shave their head and still look normal because of the eyebrows and eyelashes.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Mostaghimi A, Gooderham MJ, Lynde C, et al. Upadacitinib for severe alopecia areata in adults and adolescents: two phase 3 UP-AA randomized clinical trials. 

AbbVie. AbbVie submits application to FDA for upadacitinib (Rinvoq) for adults and adolescents with severe alopecia areata. News release. Published April 28, 2026. Accessed August 24, 2026. 

https://news.abbvie.com/2026-04-28-AbbVie-Submits-Application-to-FDA-for-Upadacitinib-RINVOQ-R-for-Adults-and-Adolescents-with-Severe-Alopecia-Areata

Articles

Two replicate phase 3 trials (UP-AA1/UP-AA2) evaluated once-daily upadacitinib 15 or 30 mg in 1399 adults/adolescents (12–17) with severe alopecia areata (SALT ≥50), long-standing disease, and frequent near-total loss. At Week 24, ~45% (15 mg) and ~54–55% (30 mg) achieved SALT ≤20 versus 1.5–3.4% with placebo, with separation by Week 8; up to 22.5% reached SALT 0. SALT ≤20 (~80% coverage) often eliminates need for wigs and permits cosmetic camouflage of residual patches; facial hair restoration also improves ocular and airway protection.

In this Q&A, Charles Lynde, MD, highlighted upadacitinib's impact on severe alopecia areata in new phase 3 data addressing the hair loss condition.

Alopecia

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Videos

Q&A: Translating UP-AA Trial Data Into Real-World Alopecia Areata Outcomes

Jennifer A. Dantzer, MD, MHS, assistant professor of pediatrics, Johns Hopkins University School of Medicine.

IMPACT-PLuS, a long-term follow-up of the Immune Tolerance Network's IMPACT trial, found 80% of children treated with 

early-life peanut oral immunotherapy (pnOIT) 

remained peanut tolerant a median of 9 years later.

Most food OIT trials report outcomes measured in months, leaving limited data on what happens to desensitization or remission once children reach adolescence.

 IMPACT was the first randomized, placebo-controlled trial to test pnOIT in children aged 1 to 3 years, showing greater desensitization and remission rates than typically reported in older cohorts.¹ IMPACT-PLuS was designed specifically to answer whether these early gains persist, following participants 8 to 11 years after their original enrollment.

"OIT is not the best treatment choice for everyone," said Jennifer A. Dantzer, MD, MHS, assistant professor of pediatrics, Johns Hopkins University School of Medicine, "but it's something a family with a food allergy could discuss with their allergist, weighing the risks and benefits to see if it makes sense for their family."

Early-Life Peanut OIT’s Decade-Long Benefit, With Jennifer Dantzer, MD

IMPACT-PLuS Trial Design and Long-Term Peanut Consumption Findings

IMPACT enrolled 146 children aged 12 to 47 months at 5 US sites, randomizing them 2:1 to pnOIT (2000 mg peanut protein daily) or placebo for 134 weeks, then 26 weeks of avoidance.¹ At the end of the trial, 71% of pnOIT-treated participants met desensitization criteria on an oral food challenge, compared with 2% of the placebo group.¹ Separately, 21% achieved remission after passing a 5000 mg peanut challenge following 26 weeks off therapy.¹

IMPACT-PLuS re-enrolled 78 of the original 146 participants (53%) between April 2023 and February 2024, then aged 9 to 14 years, a median of 9 years after their original enrollment.

 The primary analysis centered on group A, the 40 pnOIT-treated participants who pursued no additional peanut-directed intervention after IMPACT ended. In this group, 80% were still eating peanut at follow-up, and 35% were consuming ≥ 1000 mg of peanut protein in a single serving.

Across the full pnOIT follow-up cohort of 58 participants, including those who pursued additional therapy after IMPACT, 83% remained peanut tolerant.

 This continuation rate exceeds the roughly 50% long-term rate reported in earlier OIT cohorts.

Remission, Reactions, and Immunologic Changes After Early-Life pnOIT

In IMPACT-PLuS, 80% of children treated with early-life pnOIT and no subsequent intervention were still eating peanut a median of 9 years after enrollment.

All 15 participants who achieved remission in the original IMPACT trial remained peanut tolerant at follow-up, and 60% were eating at least 1000 mg of peanut protein per serving.

Reactions were reported by 35% of the pnOIT-only group since IMPACT ended.

All 15 participants from IMPACT's original remission group, those who passed a 5000 mg peanut challenge after 26 weeks of avoidance, were still eating peanut at follow-up, and none had reverted to full avoidance.

 In total, 60% were consuming ≥ 1000 mg of peanut protein per serving.

 Reactions were less frequent in this group than in participants who were desensitized without achieving remission or who were never desensitized, occurring in 14% versus 50% of those other subgroups (

Overall, 35% of group A reported an allergic reaction to peanuts since IMPACT ended, involving oral pruritus, hives, or wheezing.

 Eleven participants used medication to treat a reaction, and 5 received epinephrine.

 Eight participants (20%) had returned to peanut avoidance by follow-up, citing reactions, taste aversion, or difficulty maintaining the regimen.

"There's no test to say a patient would be fine spacing doses to an exact interval," Dantzer said. "I'd caution against spacing intervals without an allergist's guidance, since doing so could raise the risk of reactions for some patients."

Dantzer JA, Virkud YV, Cox AL, et al. Early-life peanut oral immunotherapy associated with long-term ingestion and immunologic changes. 

Upton J. VLOIT Boosts Multi-Nut Tolerance in Children, With Julia E. M. Upton, MD, MPH. HCPLive. Published January 17, 2026. Accessed August 24, 2026. 

https://www.hcplive.com/view/vloit-boosts-multi-nut-tolerance-in-children-julia-upton-md-mph

Wood R. OUtMATCH: Omalizumab and OIT Similarly Enable Allergenic Food Consumption, With Robert Wood, MD. HCPLive. Published March 9, 2026. Accessed August 24, 2026. 

https://www.hcplive.com/view/outmatch-omalizumab-oit-similarly-enable-allergenic-food-consumption-wood

IMPACT-PLuS follow-up found 80% of children treated with early-life peanut oral immunotherapy remained peanut tolerant 8 to 11 years later.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

 requiring very high mealtime doses have long lacked a concentrated insulin with a rapid onset, forcing clinicians to choose between large injection volumes and sluggish pharmacokinetics. A newly published pharmacokinetic and pharmacodynamic study on AT278, an investigational insulin aspart formulated at 500 units/mL, suggests this gap may be closing.

Ultra-Rapid U500 Aspart AT278 Aids High-Dose T2D Therapy

, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discussed the findings and their potential effect on insulin delivery for patients with high insulin requirements.

The single-center, randomized, double-blind, crossover study used a 12-hour euglycemic clamp to compare AT278 against standard-concentration insulin aspart (U100) and regular human U500 insulin in adults with type 2 diabetes and body mass index ranging from 25 to 38 kg/m². Each participant received a single subcutaneous dose of one formulation. AT278 produced significantly faster insulin absorption than both comparators, translating into a significantly greater glucose-lowering effect within the first hour.

This ultra-rapid profile held consistently across the full body mass index range studied, addressing a longstanding limitation of regular U500 insulin, which behaves more like an intermediate-acting agent despite its labeling. Regular U500 requires dosing roughly 30 minutes before meals while also serving a basal function, complicating use in patients who skip or delay meals. Because concentrated insulin volume, not units, is often the limiting factor in insulin pump selection, an ultra-rapid U500 option could allow more patients on high daily doses to use smaller, more desirable devices.

Current concentrated-insulin practice often involves off-label use of U200 insulin in pumps or manual U500 injections, both of which carry meaningful hypoglycemia risk and dosing complexity. An ultra-rapid, high-concentration analog designed for prandial dosing would represent the first option of its kind for insulin-resistant patients with type 2 diabetes on high-dose therapy. If confirmed in larger trials, AT278 could reshape how clinicians manage insulin delivery in this population, including expanding candidacy for automated insulin delivery systems currently considered unsuitable for regular U500 insulin.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Svehlikova E, Gatschelhofer C, Lackner B, et al. A new highly concentrated insulin aspart at278 (500 u/ ML ) demonstrates Ultra‐rapid pharmacokinetic and pharmacodynamic properties in type 2 diabetes regardless of bmi. Diabetes, Obesity and Metabolism. Published online July 30, 2026. 

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical successes of ultra-fast-acting insulin AT278.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Dana Rizk, MD, is a professor of medicine in the division of nephrology at the University of Alabama at Birmingham.

The Phase 3 VISIONARY trial enrolled 510 patients with biopsy-proven, high-risk IgA nephropathy (IgAN), making it the largest IgAN trial to date. The global, randomized, double-blind, placebo-controlled study was built to test whether selectively blocking APRIL, a cytokine central to the disease's underlying immune biology, could change the course of a condition typically defined by relentless kidney function decline.

“The VISIONARY trial was a phase three trial. It's a global study that enrolled patients with biopsy-proven IgA nephropathy, primary IgA nephropathy, really from all around the world, so very good representation,” Dana Rizk, MD, professor of medicine in the Division of Nephrology at the University of Alabama at Birmingham, said in an interview with HCPLive.

How VISIONARY's Design Targets APRIL in IgA Nephropathy, With Dana Rizk, MD

A High-Risk, Globally Representative IgAN Population

To enroll in VISIONARY, patients needed a biopsy confirming primary IgAN and an estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m². Rizk noted the trial built in a timing requirement tied to how preserved a patient's kidney function was at screening.

“They had to have a GFR over 30, and it might be worth mentioning that if their GFR was between 30 and 44, they had to have a biopsy within three years. If it was over 45, so, you know, pretty good preserved GFR, they could have had a biopsy at any point in time,” Rizk said.

Patients also had to meet a proteinuria threshold to qualify as high-risk: > 1 g/day of protein, or a urine protein-to-creatinine ratio > 0.75 g/g, based on a 24-hour collection.

Before randomization, all participants were optimized on background therapy reflecting current standard of care. Patients were maintained on maximum tolerated renin-angiotensin system (RAS) inhibition, and those on sodium-glucose cotransporter-2 (SGLT2) inhibitors had to be on a stable dose for at least 3 months prior to enrollment. Concomitant immunosuppressive medications were not permitted leading up to the study.

Once patients cleared screening, they were randomized to receive sibeprenlimab, 400 mg subcutaneously every 4 weeks, or placebo.

How Anti-APRIL Therapy Targets IgA Nephropathy

Sibeprenlimab is an anti-APRIL therapy, and Rizk walked through why that mechanism was chosen to target IgAN at its immunologic root.

“APRIL is a cytokine that is important in allowing B cells to become IgA-secreting cells, and also is important for the survival of B cells,” Rizk said.

IgAN is an immune-mediated disease, and its pathogenesis has been summarized by the four-hit hypothesis: overproduction of galactose-deficient IgA1 (Gd-IgA1) triggers the formation of autoantibodies against it, which in turn form circulating immune complexes. Those complexes ultimately deposit in the kidneys, driving inflammation and, over time, fibrosis.

“Targeting B cells and this immune backbone to the disease is of course important, makes sense, and that was the premise for the anti-APRIL therapy design,” Rizk said.

Sibeprenlimab (marketed as VOYXACT) received accelerated approval from the U.S. Food and Drug Administration (FDA) in November 2025 for reduction of proteinuria in adults with IgAN at risk of disease progression, based on VISIONARY's primary endpoint results. The trial's key secondary endpoint, annualized eGFR slope over 24 months, offers a longer-term view of whether that upstream mechanism translates into preserved kidney function.

include AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and others. Disclosures for

include Boehringer Ingelheim, Calliditas Therapeutics, GSK, Otsuka Pharmaceutical Co., Travere Therapeutics, and others. Disclosures for

include Novartis Pharmaceuticals, Otsuka Pharmaceutical Inc., Vera Therapeutics, Biogen, Travere Therapeutics, and others.

Perkovic V, Trimarchi H, Tesar V, et al. Sibeprenlimab in IgA nephropathy: interim analysis of a phase 3 trial. 

. 2026;394(7):635-646. doi:10.1056/NEJMoa2512133

Otsuka. Otsuka unveils unprecedented phase 3 VISIONARY two-year eGFR results demonstrating VOYXACT (sibeprenlimab-szsi) stabilizes kidney function decline to baseline physiologic rate, fundamentally altering disease progression in IgA nephropathy (IgAN). News release. August 3, 2026. 

https://www.otsuka-us.com/news/otsuka-unveils-unprecedented-phase-3-visionary-two-year-egfr-results-demonstrating-voyxactr

Rizk DV, Perkovic V, Trimarchi H, et al. Two-year eGFR and safety results from the VISIONARY phase 3 trial of sibeprenlimab in IgA nephropathy. Presented at: GlomCon Hawaii; August 3-7, 2026; Maui, HI.

VISIONARY enrolled 510 high-risk IgAN patients globally. Learn how the trial's design and anti-APRIL mechanism were built to target disease at its root.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Topline results from Part 2 of the phase 3 ABTECT maintenance trial showed obefazimod sustained clinical benefit through week 44 in patients with ulcerative colitis (UC) who had not initially responded to induction therapy, adding to positive Part 1 data released earlier this year. 

With those results in hand, Remo Panaccione, MD, professor of medicine and director of the IBD Clinic at the University of Calgary, spoke with HCPLive about where obefazimod might fit into an increasingly crowded UC treatment landscape.

"You're absolutely right that it's becoming a crowded landscape," Panaccione said.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD

How Does Obefazimod's Mechanism Set It Apart?

Obefazimod is a once-daily oral small molecule with a mechanism of action unlike anything currently available in the clinic. Rather than broadly suppressing the immune system, it works by increasing expression of miR-124, a naturally occurring microRNA that helps bring the immune system back into balance. "It's not a true immunosuppressant like some of the therapies we have," Panaccione said.

In Part 1 of the ABTECT maintenance trial, both the 25 mg and 50 mg doses of obefazimod met the primary endpoint of clinical remission at week 44, with remission rates of approximately 51% compared with 10% with placebo. Endoscopic remission, a Mayo endoscopy score of 0 among patients who entered the trial with a score of 2 or 3, was achieved by 41.5% of patients on 25 mg and 47.7% of patients on 50 mg, versus 10% on placebo. Part 2 data, released in June, showed continued benefit among patients who had not initially responded to induction therapy, with no new safety signals through 44 weeks.

Could Obefazimod Work Across Multiple Lines of Therapy?

Panaccione said the combination of oral dosing, once-daily administration, and strong efficacy makes obefazimod attractive across a range of patient populations, not just one line of therapy. "That combination of oral, once daily, is attractive from a patient perspective," he said. "And if you combine that with the efficacy we just discussed, which, without a direct comparison, is some of the strongest efficacy we've seen, and no safety signal in an expanding, large safety database, I can see this being used across multiple different patient populations."

He described a dual role: as a strong first advanced therapy option for patients who need to start one, and as a viable option later in the treatment course given the refractory population studied in ABTECT. "This can easily be slotted as a first advanced therapy in patients who need to go onto an advanced therapy," Panaccione said. "But also, because of the patient population that was studied here, in particular the patients who are refractory to other advanced therapies and JAK inhibitors, it could also slot in as a second line and or a third line therapy."

Panaccione also pointed to an early durability signal from the phase 2 program, where patients who achieved a response tended to maintain it over time. He said that pattern could reflect the drug's efficacy, its non-immunogenic profile as an oral small molecule, or its underlying mechanism of restoring immune balance.

What Should Clinicians Watch For Ahead of FDA Review?

Abivax has said it plans to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) in late fourth quarter 2026. Asked what clinicians should keep in mind as that submission approaches, Panaccione encouraged a close, independent read of the data once it's published rather than taking topline figures at face value.

He said clinicians should evaluate the published data against the phase 3 evidence that has already supported regulatory approvals for other UC therapies, paying particular attention to both absolute and placebo-adjusted efficacy numbers. "They should think about those absolute numbers and those placebo-adjusted numbers and what that's going to mean not only for their own practice, but for their patients," Panaccione said.

Editors' note: Panaccione has relevant disclosures with Abbott, AbbVie, Abivax, Alimentiv, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Ferring, Galapagos, Gilead Sciences, Janssen, Merck, Novartis, Pfizer, Takeda, and others.

Abivax announces landmark Phase 3 ABTECT maintenance trial results evaluating obefazimod in moderately to severely active ulcerative colitis. News release. Abivax. June 1, 2026. Accessed August 19, 2026. 

https://www.globenewswire.com/news-release/2026/06/01/3304711/0/en/abivax-announces-landmark-phase-3-abtect-maintenance-trial-results-evaluating-obefazimod-in-moderately-to-severely-active-ulcerative-colitis.html

Abivax reports positive ABTECT maintenance Part 2 results for obefazimod, demonstrating meaningful clinical benefit in refractory ulcerative colitis patients and strengthening the Phase 3 maintenance safety database. News release. Abivax. June 29, 2026. Accessed August 19, 2026. 

https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results/

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Jessica Mercer, MD, serves as co-managing owner of Georgia Dermatology Partners near Atlanta, Georgia.

Andrew Alexis, MD, MPH, and Jessica Mercer, MD, discuss how informal mentorship moments improve training and care for skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Does Mentorship Improve Outcomes for Patients of Color?

This episode discusses the recent results from trials of IcoSema and a new highly concentrated insulin aspart.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Ultra-Rapid Insulin, IcoSema Advance in Type 2 Diabetes

One year after FDA approval, Basavaraj discusses NTM overlap, geographic variation, and real-world access in bronchiectasis care.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Brensocatib and NTM Overlap in Bronchiectasis, With Ashwin Basavaraj, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

United Therapeutics' ralinepag NDA rests on phase 3 ADVANCE OUTCOMES data showing a 55% reduction in clinical worsening versus placebo.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

FDA News

FDA Accepts NDA for Ralinepag in Pulmonary Arterial Hypertension

Saakshi Khattri, MD, is a board certified Dermatologist, Rheumatologist and Internist and one of only a handful of triple board-certified physicians across the US.

In "Real-World Evidence and Systemic Inflammation in Psoriasis," our experts scrutinize the evidence behind popular claims about disease progression.

Video Series

Real-World Evidence and Systemic Inflammation in Psoriasis

This episode, "IL-17 Inhibitor Safety in Psoriasis: Candidiasis, IBD, and Mental Health," features the panel putting the class's safety signals in context.

IL-17 Inhibitor Safety in Psoriasis: Candidiasis, IBD, and Mental Health

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Dallas allergist-immunologists discuss real-world use of non-steroidal topicals in AD, steroid phobia, and the nematode story.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Allergists Debate: Which Nonsteroidal to Use for Atopic Dermatitis?

Andrew Alexis, MD, MPH, and Jessica Mercer, MD, discuss how mentorship shapes dermatology careers and supplements trainee education.

Why Mentorship Matters Most for Dermatology Trainees

A new study from the AHA has indicated the real prevalence of CKM syndrome stages 0-3 in young adults in their 20s.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Chronic Kidney Disease

CKM Syndrome, Artery Damage Prevalence Higher in Young Adults than Previously Believed

One year after FDA approval, Mark Metersky, MD, discusses which bronchiectasis patients benefit most from brensocatib and its safety profile.

Latest News

Q&A: Translating UP-AA Trial Data Into Real-World Alopecia Areata Outcomes

Early-Life Peanut OIT’s Decade-Long Benefit, With Jennifer Dantzer, MD

Ultra-Rapid U500 Aspart AT278 Aids High-Dose T2D Therapy

How VISIONARY's Design Targets APRIL in IgA Nephropathy, With Dana Rizk, MD

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD